EDAP International
This article was originally published in The Gray Sheet
Executive Summary
Acquires "certain assets" of Technomed International including exclusive U.S. distribution rights for Technomed's Sonolith lithotripter, Pulsolith laser lithotripter and Prostatron thermal therapy device. Earlier this year, EDAP's French parent company, EDAP International SA, "purchased the licenses, patents and manufacturing facility" of Technomed's parent in France (Technomed International SA), which had filed for bankruptcy in September 1993, according to EDAP. The company says Technomed will no longer be doing business in the U.S. A newly formed EDAP Technomed group will provide "continued sales, service and technical expertise" for Sonolith and Pulsolith customers. EDAP says it has completed 95% of a premarket approval application for the Prostatron for the treatment of benign prostrate hyperplasia and plans to submit the PMA in January 1995
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.